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OBJECTIVEdWe analyzed data from a cohort of 1,381 newly diagnosed type 2 diabetic
patients to test the hypothesis that urinary markers of nucleic acid oxidation are independent
predictors of mortality.
RESEARCH DESIGN ANDMETHODSdWe examined the relationship between urinary
excretion of markers of DNA oxidation (8-oxo-7,8-dihydro-29-deoxyguanosine [8-oxodG]) and
RNA oxidation (8-oxo-7,8-dihydroguanosine [8-oxoGuo]) and long-termmortality using Cox pro-
portional hazards regression.
RESULTSdAfter multivariate adjustment, the hazard ratios for all-cause and diabetes-related
mortality of patients with 8-oxoGuo levels in the highest quartile compared with those in the lowest
quartile were 1.44 (1.12–1.85) and 1.54 (1.13–2.10), respectively. Conversely, no signiﬁcant associ-
ations between 8-oxodG and mortality were found in the adjusted analyses.
CONCLUSIONSdUrinary excretion of the RNA oxidationmarker 8-oxoGuomeasured shortly
after diagnosis of type 2 diabetes predicts long-term mortality independently of conventional risk
factors. This ﬁnding suggests that 8-oxoGuo could serve as a new clinical biomarker in diabetes.
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Over the last decade, there has beenan increased focus on the role ofoxidative stress in the pathophysi-
ology of diabetes-related complications.
The diabetic state is associated with in-
creased levels of markers of oxidative
stress, and evidence derived from mech-
anistic studies suggests that oxidative
stress has an important role in the path-
ogenesis of diabetes complications (1–7).
Markers of intracellular oxidative stress
that could be used as new biomarkers in
diabetes are the oxidatively modiﬁed
guanine nucleosides 8-oxo-7,8-dihydro-
29-deoxyguanosine (8-oxodG) and 8-oxo-
7,8-dihydroguanosine (8-oxoGuo), which
are widely used as markers of DNA and
RNAoxidation, respectively. Thesemarkers
can conveniently be assessed in the urine,
which makes them well suited for use in
risk stratiﬁcation and therapy control.
The prognostic importance of urinary
markers of oxidative stress in patients with
type 2 diabetes is unknown. In the current
studyweuseddata fromapopulation-based
cohort of 1,381 patients newly diagnosed
with diabetes to test the hypothesis that the
urinarymarkers of oxidative stress 8-oxodG
and 8-oxoGuo are independent predictors
of mortality.
RESEARCH DESIGN AND
METHODS
Study population
In the Diabetes Care in General Practice
study (8), 474 general practitioners agreed
to include all subjects on their practice list
who fulﬁlled the following criteria: newly
diagnosed diabetes based on hyperglycemic
symptoms and/or raised blood glucose
values, diagnosed between 1 March 1989
and 28 February 1992, and aged 40 years
or over. Accordingly, a total of 1,543
newly diagnosed diabetic patients were el-
igible, but 162 were excluded because of
protocol-based exclusion criteria: life-
threatening somatic disease (50 patients),
severe mental illness (50 patients), or un-
willingness to participate (62 patients).
This gave a ﬁnal study population of
1,381 patients. Based on the onset of insu-
lin treatment within 180 days of diagnosis,
;97.5% of the patients were considered to
have type 2 diabetes (8).
The protocol was approved by the
ethics committee of Copenhagen and
Frederiksberg, and informed consent was
obtained from all patients.
Baseline assessments
The participants produced a freshly
voided morning urine sample as soon as
possible after the day of diagnosis (median
time from diagnosis to urine sample was 11
days; interquartile range, 4–29 days). Uri-
nary markers of nucleic acid oxidation were
measured at the Laboratory of Clinical Phar-
macology (Rigshospitalet, Copenhagen).
The urine samples, stored at 2808C until
analysis, were assayed between 2009 and
2010 for the oxidatively modiﬁed guanine
nucleosides 8-oxodG and 8-oxoGuo using
a validatedmethod of ultraperformance liq-
uid chromatography and tandem mass
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spectrometry (9). 8-oxodG and 8-oxoGuo
were normalized against urinary creatinine
concentration.
Outcome assessments
The vital status of all the diabetic patients
was certiﬁed on1 January 2009 through the
Danish Civil Registration System (10).
Diabetes-related death was deﬁned as
at least one of the following entries in the
Danish National Register of Causes of Death
(11): suddendeathordeath frommyocardial
infarction, stroke, renal disease, hypergly-
cemia, hypoglycemia, or peripheral vascular
disease.
Statistical analysis
The associations between oxidative stress
and all-cause mortality and diabetes-related
mortality, respectively, were analyzed in
Cox proportional hazards regression mod-
els based on time fromdiagnosis to death or
censoring. Oxidative stress is represented
by the natural logarithm of 8-oxodG and 8-
oxoGuo, and by a four-class ordinal vari-
able corresponding to the quartiles of the
distribution. Three models were estimated
for each of the oxidative stress variables and
each of the outcomes: a univariate (unad-
justed) model, a model adjusted for age and
sex, and a multivariate model. Covariates
included in the multivariate model were
age, sex, smoking status, cohabitation sta-
tus, physical activity, education, BMI, pres-
ence or absence of hypertension and of
microalbuminuria, glycated hemoglobin,
total cholesterol, triglycerides, serum cre-
atinine, presence or absence of retinopathy
and of peripheral neuropathy, and history
of acute myocardial infarction and stroke.
RESULTSdBaseline characteristics ac-
cording to quartiles of 8-oxodG and 8-
oxoGuo are provided in Supplementary
Tables 1 and 2. After a median follow-up
period of 18.7 years (interquartile range,
18.2–19.2 years), 966 (70.0%) patients
had died, of whom 584 were regarded as
having had a diabetes-related death. The re-
sults of the unadjusted and adjusted Cox
regression analyses are shown in Table 1.
In the adjusted analyses, only 8-oxoGuo
was signiﬁcantly associated with mortality.
The multivariate adjusted hazard ratios for
all-cause and diabetes-related mortality of
patients with 8-oxoGuo levels in the highest
quartile compared with those in the lowest
quartile were 1.44 (95% CI 1.12–1.85; P =
0.004) and 1.54 (1.13–2.10; P = 0.006),
respectively.
When log 8-oxodG and log 8-oxoGuo
were considered as continuous covariates,
the results were similar to those described
above. The multivariate adjusted hazard
ratios for all-cause and diabetes-related
mortality per unit increase in log 8-oxoGuo
were 1.33 (95% CI 1.07–1.64; P =
0.009) and 1.40 (1.08–1.81; P = 0.01),
respectively.
CONCLUSIONSdThis study is, to our
knowledge, the ﬁrst to explore the associ-
ation between urinary excretion of mark-
ers of oxidative stress and mortality in
diabetic patients. Urinary excretion of the
RNA oxidation marker 8-oxoGuo in a fresh-
ly voided morning urine sample shortly
after diagnosis of diabetes independently
Table 1dRelationship of 8-oxodG and 8-oxoGuo with all-cause and diabetes-related mortality
Outcome
Unadjusted hazard
ratio (95% CI) P
Age- and sex-adjusted
hazard ratio (95% CI) P
Multivariate-adjusted
hazard ratio (95% CI)* P
All-cause mortality
8-oxodG
1st Quartile 1.0 1.0 1.0
2nd Quartile 0.99 (0.83–1.19) 0.93 0.88 (0.73–1.07) 0.20 1.00 (0.78–1.28) 0.98
3rd Quartile 0.95 (0.79–1.14) 0.60 0.81 (0.67–1.97) 0.03 0.91 (0.71–1.15) 0.41
4th Quartile 1.35 (1.13–1.61) 0.001 1.00 (0.83–1.20) 0.99 1.07 (0.84–1.37) 0.58
Log 8-oxodG 1.30 (1.11–1.51) 0.001 1.12 (0.87–1.19) 0.82 1.01 (0.82–1.25) 0.91
8-oxoGuo
1st Quartile 1.0 1.0 1.0
2nd Quartile 1.01 (0.84–1.23) 0.88 0.89 (0.73–1.08) 0.23 0.96 (0.74–1.23) 0.73
3rd Quartile 1.37 (1.14–1.65) ,0.001 0.95 (0.79–1.15) 0.61 1.04 (0.81–1.33) 0.77
4th Quartile 2.05 (1.71–2.45) ,0.001 1.44 (1.19–1.74) ,0.001 1.44 (1.12–1.85) 0.004
Log 8-oxoGuo 1.97 (1.70–2.28) ,0.001 1.40 (1.19–1.65) ,0.001 1.33 (1.07–1.64) 0.009
Diabetes-related mortality
8-oxodG
1st Quartile 1.0 1.0 1.0
2nd Quartile 0.99 (0.79–1.26) 0.97 0.88 (0.69–1.11) 0.28 1.08 (0.79–1.74) 0.63
3rd Quartile 0.95 (0.75–1.20) 0.68 0.78 (0.61–0.98) 0.04 0.99 (0.74–1.34) 0.97
4th Quartile 1.32 (1.05–1.66) 0.02 0.98 (0.77–1.23) 0.83 1.21 (0.89–1.65) 0.22
Log 8-oxodG 1.25 (1.03–1.53) 0.03 0.97 (0.79–1.18) 0.73 1.10 (0.85–1.42) 0.49
8-oxoGuo
1st Quartile 1.0 1.0 1.0
2nd Quartile 0.99 (0.77–1.28) 0.96 0.89 (0.69–1.14) 0.36 1.03 (0.74–1.39) 0.94
3rd Quartile 1.36 (1.07–1.73) 0.01 0.92 (0.72–1.17) 0.50 1.00 (0.73–1.36) 0.99
4th Quartile 2.13 (1.69–2.69) ,0.001 1.50 (1.18–1.91) ,0.001 1.54 (1.13–2.10) 0.006
Log 8-oxoGuo 2.03 (1.69–2.45) ,0.001 1.48 (1.21–1.82) ,0.001 1.40 (1.08–1.81) 0.01
*Covariates included in the multivariate model were age, sex, smoking status, cohabitation status, physical activity, education, BMI, presence or absence of hy-
pertension and of microalbuminuria (urinary albumin $15 mg/L), glycated hemoglobin, total cholesterol, triglycerides, serum creatinine, presence or absence of
retinopathy and of peripheral neuropathy, and history of acute myocardial infarction and stroke.
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predicted all-cause and diabetes-related
mortality, whereas the DNA oxidation
marker 8-oxodG did not. The risk of death
among those in the highest quartile of
8-oxoGuoexcretionwas nearly 50%higher
than among those in the lowest quartile.
Theprognostic informationof8-oxoGuo
was independent of other characteristics
of patients with type 2 diabetes that have
been linked to mortality, most importantly
age, sex, glycated hemoglobin, lipids, uri-
nary albumin excretion, blood pressure,
smoking, and pre-existing cardiovascular
disease.
This observation suggests thatmeasure-
ment of urinary 8-oxoGuo provides addi-
tional information about risk and might be
useful for identifying patients who would
beneﬁt the most from intensiﬁed treatment
or speciﬁc treatment strategies, including
nonpharmacological interventions. The
combined use of 8-oxoGuo and other
known risk factors in a multivariate risk
factor approach could be useful for im-
proving risk stratiﬁcation of diabetic pa-
tients. 8-oxoGuo is a prime candidate for
further investigation to establish the exact
mechanisms responsible for its association
with mortality in diabetic patients, and to
evaluate its potential role as a clinical bio-
marker in diabetes.
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